Linperlisib
- Generic Name
- Linperlisib
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37FN6O5S
- CAS Number
- 1702816-75-8
- Unique Ingredient Identifier
- 05HYK3CV9N
- Indication
用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06083701
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing/China, China
🇨🇳Beijing Hospital, Beijing, China
Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
- Conditions
- Cutaneous T-cell Lymphoma
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06037239
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT05949944
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
Real World Study of Linperlisib for Lymphoma Treatment
- Conditions
- Focus on the Lymphoma Including B/T-cell Lymphoma
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05863871
- Locations
- 🇨🇳
Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital, Tianjin, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
- Conditions
- Autoimmune Hemolytic AnemiaFailure of Two Rounds of Treatment
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 4
- Registration Number
- NCT05676697
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Conditions
- Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-05-29
- Target Recruit Count
- 8
- Registration Number
- NCT05676710
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05429398
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT05274997
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
- Conditions
- Effectiveness，Safety，Thymic Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04975061
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.